HC Wainwright & Co. Maintains Buy on Cara Therapeutics, Raises Price Target to $35
HC Wainwright & Co. analyst Oren Livnat maintains Cara Therapeutics (NASDAQ:CARA) with a Buy and raises the price target from $33 to $35.
Arena Pharma, GrowGen & HEXO Among Top Cannabis Stock Movers On August 23, 2021
GAINERS:
iAnthus Capital Hldgs (OTC:ITHUF) shares closed up 35.27% at $0.28 with an estimated market cap of $48,870,997.
Cara Therapeutics And Vifor Pharma Announce FDA Approval Of KORSUVA For Treatment Of Moderate-To-Severe Pruritus In Hemodialysis Patients
First and only therapy approved by the FDA for the treatment of pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis
Promotional launch of KORSUVA™ injection in the U.S. is
The Week Ahead In Biotech: Cara FDA Decision, Ascendis Earnings, Aileron Data Presentation And More
Biotech stocks swayed back and forth before ending the week lower. With earnings news dying down and an empty initial public offerings calendar, it was broader market cues, clinical readouts and regulatory actions that moved stocks during the week.
Bearish Wave Dumps Marijuana Stocks – GrowGeneration Sundial Growers And Aurora Cannabis Among Top Cannabis Movers For Today – Tilray Down By 6%
GAINERS:
Cipher Pharms Inc (OTC:CPHRF) shares closed up 20.19% at $1.62 with an estimated market cap of $43,398,257.
Top Marijuana Stocks, Movers For August 10, 2021
GAINERS:
Body and Mind (OTC: BMMJ) shares closed up 18.92% at $0.44 with an estimated market cap of $47,994,222.
Cara Therapeutics: Q2 Earnings Insights
Shares of Cara Therapeutics (NASDAQ:CARA) decreased in after-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share decreased 12.96% year over year to ($0.61), which missed the estimate of ($0.53).
Cara Therapeutics Q2 EPS $(0.61) Misses $(0.53) Estimate
Cara Therapeutics (NASDAQ:CARA) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate of $(0.53) by 15.09 percent. This is a 12.96 percent decrease over losses of $(0.54) per share
Earnings Scheduled For August 9, 2021
Companies Reporting Before The Bell
• Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $1.57 per share on revenue of $215.17 million.